English Emily
Known title: SVP, Head of ManufacturingCIK: 0002019791
Associated companies
Transaction History
| RNAC | ▲ Buy | Grant | 24,000 | $0 | 1/2/2026 | View on chart |
| RNAC | ▲ Buy | Option Exercise | 7,500 | $25K | 12/30/2025 | View on chart |
| RNAC | ▲ Buy | Option Exercise | 7,500 | $25K | 11/28/2025 | View on chart |
| RNAC | ▲ Buy | Option Exercise | 7,500 | $25K | 5/12/2025 | View on chart |
| RNAC | ▲ Buy | Option Exercise | 7,500 | $25K | 4/15/2025 | View on chart |
| RNAC | ▼ Sell | Open Market | 906 | $15K | 1/6/2025 | View on chart |
| RNAC | ▼ Sell | Open Market | 891 | $15K | 1/3/2025 | View on chart |
| RNAC | ▲ Buy | Grant | 16,100 | $0 | 1/2/2025 | View on chart |
| RNAC | ▲ Buy | Option Exercise | 7,650 | $25K | 12/26/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
RNAC Presents New Retreatment Data for Descartes-08 at MGFA Session
Cartesian Therapeutics shared additional retreatment data for its lead candidate Descartes-08 in patients with generalized myasthenia gravis. The results were presented at the MGFA scientific session of the 2026 AANEM annual meeting. This update adds to the company's clinical development information and may influence future regulatory discussions.
RNAC Presents New Retreatment Data for Descartes-08 at MGFA Session. Cartesian Therapeutics shared additional retreatment data for its lead candidate Descartes-08 in patients with generalized myasthenia gravis. The results were presented at the MGFA scientific session of the 2026 AANEM annual meeting. This update adds to the company's clinical development information and may influence future regulatory discussions.